Other languages Better Therapeutics, Inc.

Equities

BTTX

US08773T1043

Market Closed - OTC Markets Other stock markets 01:05:30 30/04/2024 am IST			5-day change	1st Jan Change
0.012 ^USD	+20.00%		+96.72%	-93.85%

21/03	Better Therapeutics, Inc. Receives Notice of Default from Hercules Capital, Inc	CI
20/03	Better Therapeutics, Inc.(NasdaqCM:BTTX) dropped from S&P TMI Index	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Better Therapeutics, Inc. Receives Notice of Default from Hercules Capital, Inc	22/03
Sector Update: Health Care Stocks Lower Thursday Afternoon	14/03
Better Therapeutics to Terminate Employees, Explore Strategic Alternatives; Shares Drop Sharply	14/03
Better Therapeutics' Platform Targeting Advanced Liver Disease Receives FDA Breakthrough Device Designation	20/02
Better Therapeutics, Inc. Receives FDA Breakthrough Device Designation for Digital Therapeutic Platform Targeting Advanced Liver Disease	20/02
Better Therapeutics Inc. Announces Publication of Cost-Effectiveness Analysis Demonstrating AspyreRx Is More Effective and Less Costly Than Standard of Care Alone	17/01
Better Therapeutics and Glooko Announce Partnership to Accelerate Adoption of AspyreRx to Treat Type 2 Diabetes in the United States	03/01
Better Therapeutics Seeks FDA Breakthrough Device Designation for Prescription Digital Therapeutics Targeting Liver Diseases	02/01
Better Therapeutics, Inc. Announces Submission for FDA Breakthrough Device Designation for Digital Therapeutic Platform to Treat Liver Disease	02/01
Better Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
SHARES OF BETTER THERAPEUTICS UP 24.4% AFTER CO ANNOUNCES LAUNCH…	16/23/16
Better Therapeutics, Inc. Announces New Data Highlighting Concurrent Use of AspyreRx and GLP-1 Receptor Agonists to Treat Type 2 Diabetes	11/23/11
Better Therapeutics Says Study of Novel Cognitive Behavioral Therapy Platform Meets Endpoints	05/23/05
Better Therapeutics Completes Enrollment in Study Evaluating Long-term Effectiveness of AspyreRx in Type 2 Diabetes	29/23/29
Better Therapeutics, Inc. Completes Enrollment in Real-World Evidence Program Evaluating Long-term Effectiveness of AspyreRx in Type 2 Diabetes	29/23/29
Better Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/23/10
Insider Buy: Better Therapeutics	31/23/31
Insider Buy: Better Therapeutics	31/23/31
MÄRKTE USA/Wall Street setzt auf niedrige Inflation	12/23/12
Aktien New York: China-Konjunkturmassnahmen stützen den Dow	11/23/11

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Better Therapeutics, Inc.

Equities

BTTX

US08773T1043

Other languages

Filters